Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K^sup +^ chann...
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K^sup +^ channels in chronic myelogenous leukemia
About this item
Full title
Author / Creator
Zheng, Fang , Li, Huiyu , Liang, Kaiwei , Du, Yimei , Guo, Dongmei and Huang, Shiang
Publisher
Middlesex: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Middlesex: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Imatinib is a powerful protein tyrosine kinase (PTK) inhibitor that specifically targets BCR-ABL, KIT, and PDGFR kinases, has become the current first-line therapy for all newly diagnosed chronic myeloid leukemia (CML). Beside PTKs, PTK inhibitors alter the activity of a large number of voltage-dependent ion channels. hERG1 K^sup +^ channels are hi...
Alternative Titles
Full title
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K^sup +^ channels in chronic myelogenous leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1037269967
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1037269967
Other Identifiers
ISSN
1357-0560
E-ISSN
1559-131X
DOI
10.1007/s12032-011-0102-y
